miR-183, downregulated in melanoma, targets integrin subunit beta 1 (ITGB1) which is associated with tumor growth, metastasis and drug resistance [134], and miR-22 inhibits the expression of EMT-promoting MMP14 and Snail transcription factors [135]. This evidence concerns the gene ITGB1 and melanoma.